• Enforced expression of the transcription factors PU.1, IRF8, and BATF3 (PIB) was sufficient to induce the cDC1 phenotype in 36 cell lines derived from human and mouse hematological and solid tumors. (lu.se)
  • Cytovia is the first company to combine its own iPSC-derived natural killer (iNK) cells and multispecific, NK cell-engaging antibodies and is building a pipeline that encompasses both hematological malignancies and solid tumors. (biospace.com)
  • A technical limitation of CAR-T technology is that it is challenging for CAR T-cells to target solid tumors. (tufts.edu)
  • At the moment, the therapy is most effective against hematological (blood) cancers but not solid tumors. (tufts.edu)
  • To solve this problem, the biopharmaceutical Celyad is developing a CAR-T that expresses Natural Killer Receptors (NKR) that can bind ligands of solid tumors. (tufts.edu)
  • While immunotherapies have shown great promise in treating blood cancers, most clinical trials aimed at treating solid tumors such as pancreatic or lung cancer have failed. (medicalxpress.com)
  • Researchers have long thought that solid tumors' resistance to treatment is due to the tumor microenvironment-the cells and matrix that surround solid tumors-but the exact mechanisms behind this blockade were unclear, until now. (medicalxpress.com)
  • The researchers say that using a dual approach-by first targeting cancer-associated fibroblasts and then sending in tumor-targeting CAR T cells-could be a therapeutic breakthrough for treatment-resistant solid tumors. (medicalxpress.com)
  • Solid tumors are surrounded by a matrix of cells and fibrous connective tissue called "stroma. (medicalxpress.com)
  • Previous studies have shown that stroma plays a role in preventing T cells from attacking solid tumors, but it was unclear how. (medicalxpress.com)
  • In some experiments, after treating the solid tumors in the mice with fibroblast -targeting CAR T cells, the researchers followed-up by treating the tumors with another set of CAR T cells that had been engineered to target a tumor antigen called mesothelin. (medicalxpress.com)
  • Though mesothelin-targeting CAR T cells are effective at targeting cancer cells in vitro, previous clinical trials in humans have shown that they are ineffective at treating solid tumors in patients. (medicalxpress.com)
  • HexaBody-CD27 is currently being evaluated in patients with advanced solid tumors ( NCT05435339 ). (bmj.com)
  • This review summarizes the use of high-voltage electrical pulses (HVEPs) in clinical oncology to treat solid tumors with irreversible electroporation (IRE) and electrochemotherapy (ECT). (rsna.org)
  • Roitt's Essential Immunology, 11th Ed. ISBN 978-1-4051-3603-7 The impact of food bioactives on gut health : in vitro and ex vivo models. (wikipedia.org)
  • In addition to acquiring improved antigen presentation, tumor-APCs had impaired tumorigenicity in vitro and in vivo. (lu.se)
  • Aim of the present work was to investigate in vitro and in vivo the possible involvement of autophagy, and its modulation in the control of GSC survival and death. (nature.com)
  • The FLEX-NK TM tetravalent, multifunctional antibody CYT-303 directed against NKp46 and GPC3 demonstrated in vitro and in vivo activity against HCC tumor targets. (biospace.com)
  • The combination of the FLEX-NK TM and iNK platforms demonstrated greater in vitro and in vivo anti-tumor activity in HCC models than iNK cells alone, with a favorable in vitro cytokine release and immune cell subset safety profile. (biospace.com)
  • This immunotherapy approach attempts to overcome the patient's tolerance towards cancer cells and tumor-induced immunosuppression by activating and modifying the patient's T cells outside the body (ex vivo). (medigene.com)
  • Transfer of HSV-tk to DLI preserves the beneficial anti-tumor effect and allows in vivo elimination of donor T cells if severe GvHD occurs. (haematologica.org)
  • The development of such therapeutic molecules required robust preclinical investigations to determine their toxicity profiles in animals, the normal tissue-binding specificities, and to demonstrate their selective anti-tumor activity both in vitro and in vivo. (atsbio.com)
  • When the same two immunotoxins were used individually in vivo in SCID mice xenografted with the same ALL cell line, they exerted therapeutic activity in line with the data obtained from the in vitro study. (atsbio.com)
  • Pharmacological and macrophage-specific genetic ablation of β-catenin reprogrammed M2-like TAMs to M1-like TAMs both in vitro and in various in vivo models, which was linked with the suppression of primary and metastatic lung tumor growth. (uni-frankfurt.de)
  • This enabled them to demonstrate a distinct impact of tissue viscoelasticity on T cell development and function in vitro and in vivo , and to identify a molecular pathway driving the phenomenon. (sciencedaily.com)
  • Unfortunately, their clinical value is limited by their rapid loss of function and failure to expand in vivo, presumably due to the lack of costimulator molecules on tumor cells and the inherent limitations of signaling exclusively through the chimeric receptor. (nih.gov)
  • Our clinical studies have shown that EBV-specific T cells generated in vitro will expand, persist, and function for more than 6 years in vivo. (nih.gov)
  • Both in vitro and in vivo evaluations showed that SAR408701 has cytotoxic activity, leading to in vivo efficacy in single and repeated dosing. (nih.gov)
  • I labeled the very late antigen (VLA-4) targeted LLP2A tracer with copper-64 for PET imaging (64Cu-LLP2A) and observed target-selective binding and internalization in vitro, as well as robust tumor uptake and retention in vivo. (pitt.edu)
  • Our ex vivo patient-specific GBM-on-a-Chip provides an avenue for a personalized screening of immunotherapies for GBM patients. (elifesciences.org)
  • Novel understanding in the interaction between immune system and cancer cells of the patient holds great promise for immunotherapy development [ 4 - 6 ]. (hindawi.com)
  • This CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. (moffitt.org)
  • As the field of cancer immunotherapy advances rapidly, it is now crucial to understand how the dissemination and maintenance of tumor-specific T cells can be optimally achieved. (frontiersin.org)
  • Taken together, these data indicate that γδ T cells contribute to the response to immune checkpoint blockade in patients with HLA-class-I-negative MMR-d colon cancers, and underline the potential of γδ T cells in cancer immunotherapy. (nki.nl)
  • The successful campaign of adoptive T cell therapies, a type of immunotherapy in which immune T cells are collected from a patient, enhanced outside of the body, and reinfused back into the same patient, especially against blood cancers is well under way. (sciencedaily.com)
  • Breast tumor infiltrating lymphocytes (TIL) are enriched in tumor-specific cytotoxic T lymphocytes (CTL), and may represent a superior source of CTL compare to peripheral blood lymphocytes (PBL), for adoptive T cell immunotherapy of breast cancer. (utmb.edu)
  • Combined TRT and immune checkpoint immunotherapy (ICI) has demonstrated remarkable responses even in poorly immunogenic tumors both preclinically and in patients. (pitt.edu)
  • With the explosion in tumor immunotherapy research in recent years, there is growing interest in finding agents to increase the cytotoxic activity of immune cells to improve patient outcomes. (jove.com)
  • Immunotherapy was shown to significantly increase the rate of the abscopal effect and prolong patient survival. (nature.com)
  • Immune-inflamed tumors are called hot tumors, while the latter two are collectively referred to as cold tumors, and they respond poorly to immunotherapy. (nature.com)
  • Background Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. (unav.edu)
  • Programmed cell death protein-1 (PD-1) checkpoint immunotherapy efficacy remains unpredictable in glioblastoma (GBM) patients due to the genetic heterogeneity and immunosuppressive tumor microenvironments. (elifesciences.org)
  • Here, we report a microfluidics-based, patient-specific 'GBM-on-a-Chip' microphysiological system to dissect the heterogeneity of immunosuppressive tumor microenvironments and optimize anti-PD-1 immunotherapy for different GBM subtypes. (elifesciences.org)
  • Immunotherapy can fail in patients with cancer when certain cancer cells can hide from the immune system. (lu.se)
  • However, cDC1 can be compromised in cancer patients and some cancer cells lack these antigen-presenting proteins on their surface, impacting immunotherapy response. (lu.se)
  • Decreased antigen presentation contributes to the ability of cancer cells to evade the immune system. (lu.se)
  • We used the minimal gene regulatory network of type 1 conventional dendritic cells (cDC1) to reprogram cancer cells into professional antigen-presenting cells (tumor-APCs). (lu.se)
  • Within 9 days of reprogramming, tumor-APCs acquired transcriptional and epigenetic programs associated with cDC1 cells. (lu.se)
  • Reprogramming restored the expression of antigen presentation complexes and costimulatory molecules on the surfaces of tumor cells, allowing the. (lu.se)
  • Human primary tumor cells could also be reprogrammed to increase their capability to present antigen and to activate patient-specific tumor-infiltrating lymphocytes. (lu.se)
  • Our approach serves as a platform for the development of immunotherapies that endow cancer cells with the capability to process and present endogenous tumor antigens. (lu.se)
  • Reprogramming cancer cells to antigen-presenting cells. (lu.se)
  • Tissue sample from 30-year-old primigravida patient face epithelial cells and scattered luminal histiocytes of the exposed to seasonal infl uenza (H1N1). (cdc.gov)
  • The genetically modified autologous T cells are expanded in vitro at a production facility and then reinfused into the patient. (medscape.com)
  • Chimeric antigen receptors (CARs) are synthetic proteins expressed on the surface of T cells. (medscape.com)
  • Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
  • However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
  • Various biological processes including immunoreaction of infection, tumor prevention, and human aging could cause telomere damage, tumor-related stress responses, and T regulatory (Treg) cells activation, which even trigger T cell senescence showing the distinctive phenotypic and functional alternation [ 9 , 10 ]. (hindawi.com)
  • Immunotherapies include checkpoint inhibitory antibodies, chimeric antigen receptor (CAR) T-cells, cancer vaccines, and oncolytic viruses. (moffitt.org)
  • Dendritic cells can be used as a vaccine by preparing together with either peptides or small portions of tumor antigens and they can then be injected into the body. (moffitt.org)
  • They're injecting HER2 pulsed dendritic cells (MCC 20915) made from the patient back into their breast tumor before chemotherapy. (moffitt.org)
  • The active components of CMN-001 are autologous, matured dendritic cells, which have been co-electroporated with both in vitro transcribed (IVT) RNA from an autologous tumor specimen and CD40L RNA. (moffitt.org)
  • Recent studies in mouse tumor models have shown that T RM cells are induced by cancer vaccines delivered in peripheral tissue sites, or by the depletion of regulatory T cells. (frontiersin.org)
  • Such tumor-specific T RM cells are recognized as both necessary and sufficient for long-lived protection against tumors in peripheral tissue locations. (frontiersin.org)
  • In addition to highlighting key studies that directly implicate T RM cells in anti-tumor immunity, we will highlight earlier work that implicitly suggested their importance. (frontiersin.org)
  • Cancer can be considered a disease of immune dysfunction, with a failure of immune recognition leading to the outgrowth of malignant cells as tumors ( 1 ). (frontiersin.org)
  • Tumor development has been said to occur in three distinct steps: inefficient elimination of early transformed cells, development of a state of equilibrium between tumor cells and immune cells, and tumor escape from immune pressure ( 2 ). (frontiersin.org)
  • While innate immune cells are important for early tumor immune surveillance, T cells are fundamentally recognized for their crucial role in the antigen-specific recognition and elimination of malignantly transformed cells ( 2 ). (frontiersin.org)
  • Following effective priming in lymph nodes, T cells traffic to tumors and other peripheral tissues. (frontiersin.org)
  • In a growing number of cases, CD8 T cells have been shown to mediate the regression of large bulky tumors, resulting in durable long-term disease remissions ( 5 ). (frontiersin.org)
  • In the early 2000's, large and persistent populations of antigen (Ag)-specific CD8 T cells in peripheral tissues were initially classified as T EM cells in recirculation from the blood ( 8 , 11 ). (frontiersin.org)
  • Cytovia's GPC3-directed NK-engager in combination with iPSC-derived NK cells demonstrated impressive anti-tumor activity in mice that merits clinical development," added Dr. Michael Friedman , a member of Cytovia's Board of Directors. (biospace.com)
  • In vitro, PD-1 + γδ T cells that were isolated from MMR-d colon cancers exhibited enhanced reactivity to human leukocyte antigen (HLA)-class-I-negative MMR-d colon cancer cell lines and B2M-knockout patient-derived tumour organoids compared with antigen-presentation-proficient cells. (nki.nl)
  • By comparing paired tumour samples from patients with MMR-d colon cancer that were obtained before and after dual PD-1 and CTLA-4 blockade, we found that immune checkpoint blockade substantially increased the frequency of γδ T cells in B2M-deficient cancers. (nki.nl)
  • CAR-T treatment involves the infusion of transgenic T-cells that express a Chimeric Antigen Receptor (CAR) on their cell membrane into the patient. (tufts.edu)
  • The most common procedure involves isolation of the patient's own T-cells, which are then genetically modified and expanded in vitro . (tufts.edu)
  • These transgenic T-cells are then infused back into the patient to specifically target tumor cells. (tufts.edu)
  • When activated, the T-cells mediate killing of tumor cells by two mechanisms: (1) secretion of granzymes and (2) activation of death receptor signaling in the tumor cell. (tufts.edu)
  • In a new study , University of Pennsylvania researchers reveal how the tumor microenvironment prevents T cells from attacking tumors. (medicalxpress.com)
  • Using mouse models, they showed that cancer-associated fibroblasts along with extracellular matrix within the tumor microenvironment create a physical barrier to T cell entry, and these cells also actively suppress T cell function. (medicalxpress.com)
  • When the researchers used CAR T cells to target and remove these fibroblasts, rather than targeting the tumor cells themselves, T cells were able to infiltrate and attack the tumor. (medicalxpress.com)
  • The physical barrier and immunosuppressive environment derived from cancer-associated fibroblasts limits or traps T cells and prevents them from entering into the tumor," says first author Zebin Xiao, a physician and postdoctoral researcher in the School of Veterinary Medicine. (medicalxpress.com)
  • Then, they used live imaging to observe interactions between the CAR T cells, the stroma, and the tumor cells within a mouse model of pancreatic cancer. (medicalxpress.com)
  • They found that removing these cancer-associated fibroblasts effectively broke down the physical barrier surrounding the pancreatic cancer cells so that T cells could infiltrate the tumor. (medicalxpress.com)
  • The treatment also disrupted the immunosuppressive environment so that, once they had infiltrated, T cells and other immune cells could effectively attack the tumor cells . (medicalxpress.com)
  • When administered after treatment with stroma-targeting CAR T cells, mesothelin-targeting CAR T cells were able to enter the tumor and carry out their function. (medicalxpress.com)
  • Efficacy was dependent on the number of CD8+ T cells able to recognize tumor antigens that infiltrated the malignant tissue. (unav.edu)
  • The authors, scientists at Medigene, describe the use of 3D spheroids generated from tumor cell lines for assessment of TCR efficacy or healthy cells for evaluation of potential TCR-derived toxicity. (medigene.com)
  • TCR-transduced T cells showed efficient killing of tumor cell spheroids, confirming the results generated previously in a 2D system. (medigene.com)
  • The TCR-T technology aims at arming the patient's own T cells with tumor-specific T cell receptors. (medigene.com)
  • The receptor-modified T cells are then able to detect and efficiently kill tumor cells. (medigene.com)
  • The aim of adoptive T-cell therapy of cancer is to selectively confer immunity against tumor cells. (haematologica.org)
  • The use of CD20 as suicide gene was investigated in CMV specific T cells and in T cells genetically modified with an antigen specific T-cell receptor. (haematologica.org)
  • 1 , 2 The anti-tumor effect of DLI is mediated by donor T cells recognizing allo-antigens on the malignant cells of the recipient. (haematologica.org)
  • Donor T cells may also induce GvHD due to recognition of allo-antigens on non-malignant tissues of the patient. (haematologica.org)
  • T-cell receptor (TCR) gene transfer is an attractive strategy for rapid in vitro generation of high numbers of antigen specific T cells. (haematologica.org)
  • 4 In addition, TCRs for minor histocompatibility antigens, including HA-1 and HA-2, have been transferred to donor-derived virus-specific T cells to treat patients with hematologic malignancies after allogeneic stem cell transplantation. (haematologica.org)
  • Although human CD20 has previously been described as functional selection marker and suicide gene after retroviral transfer to T lymphocytes, 9 , 10 the specificities of these T cells were unknown, and therefore a potential effect of CD20 on antigen-specific T-cell functions could not be investigated. (haematologica.org)
  • Cytotoxic activity of claudin-6-specific human CD8 + T cells towards MDA-MB-231 tumor cells expressing cognate antigen was analyzed using real-time analysis of tumor cell mass, along with flow cytometric analysis of granzyme B and CD107a expression on CD8 + T cells. (bmj.com)
  • Results Combination treatment with HexaBody-CD27 and all tested anti-PD-(L)1 antibodies enhanced proliferation and proinflammatory cytokine secretion of antigen-specific CD8 + T cells in coculture with cognate antigen-expressing dendritic cells, compared to the respective single-agent treatments. (bmj.com)
  • Furthermore, the combination increased granzyme B and CD107a expression by antigen-specific CD8 + T-cells and enhanced CD8 + T-cell-mediated cytotoxic activity towards cognate antigen-expressing tumor cells. (bmj.com)
  • In this study, we comprehensively screened HLA-A2 restricted MAGE-A3 tumor epitopes and characterized the corresponding TCRs using in vitro artificial antigen presentation cells (APC) system, single-cell transcriptome and TCR V(D)J sequencing, and machine-learning. (thno.org)
  • We identified the HLA-A2 restricted T cell epitopes from MAGE-A3 that could effectively induce the activation and cytotoxicity of CD8+ T cells using artificial APC in vitro . (thno.org)
  • Importantly, T cells artificially expressing the MAGE-A3-Mp4 specific TCRs exhibited strong MAGE-A3+ tumor cell recognition and killing effect. (thno.org)
  • Newswise - HOUSTON -- Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs them into a stronger T cell type that persists longer than its comrades, researchers at The University of Texas MD Anderson Cancer Center report in Cancer Immunology Research, a journal of the American Association for Cancer Research. (newswise.com)
  • Producing more central memory T cells in vitro can address this persistence challenge and increase the effectiveness of cellular therapies," Yee notes. (newswise.com)
  • Present cellular therapies include chimeric antigen receptor T cells - genetically modified to attack a specific target and used to treat B cell blood cancers - and tumor-infiltrating leukocytes harvested from tumors used to treat melanoma. (newswise.com)
  • Yee and colleagues are developing another technique, endogenous T cells, which identifies and harvests tumor-attacking T cells in the blood. (newswise.com)
  • All three techniques rely on expanding the T cells in the lab before re-infusing them into patients. (newswise.com)
  • Cellular therapies produce mainly effector CD8-positive T cells that are fully differentiated to attack cells bearing specific antigens. (newswise.com)
  • DNAJB7-specific T cells were capable of killing colorectal tumor lines in vitro, and the IFN-gamma+ response was markedly magnified by control of immunosuppression with cyclophosphamide in cancer patients. (cardiff.ac.uk)
  • Conclusion: This study highlights how prior methods that sequence whole tumor fractions (i.e. inclusive of alive/dead stromal cells) for antigen identification may have limitations. (cardiff.ac.uk)
  • Targeting tumor cells or the tumor microenvironment (TME) are the two major fundamental principles for antitumor therapies. (biomedcentral.com)
  • The oncogenic communication with tumor cells and through the crosstalk of autocrine and paracrine components in almost all tumor types are responsible for this phenomenon. (biomedcentral.com)
  • Tumor-infiltrating immune cells are an important component of the TIME and are a significant predictor of cancer patients' survival. (biomedcentral.com)
  • The crosstalk between pro-tumorigenic immune cells, stromal cells, and cytokines helps to establish the pre-metastatic niche for disseminated circulatory tumor cells and facilitates metastasis. (biomedcentral.com)
  • During the tumor initiation stage, cancer cells escape from immune surveillance. (biomedcentral.com)
  • During metastasis, tumor-derived exosomes help in the requirement and arrangement of immunosuppressive immune cells for favorable premetastatic niche formation and growth of metastases. (biomedcentral.com)
  • The stromal component interacts with tumor cells in complex crosstalk to support tumor growth. (biomedcentral.com)
  • Researchers have engineered a tissue-mimicking hydrogel model to show that more elastic tissues induce T cells to become effector-like T cells with strong tumor-killing potential, while more viscous tissues induce them to become memory-like T cells. (sciencedaily.com)
  • Researchers at Harvard's Wyss Institute and Harvard SEAS led by David Mooney engineered a tissue-mimicking hydrogel model to show that more elastic tissues induce T cells to become effector-like T cells with strong tumor-killing potential, while more viscous tissues induce them to become memory-like T cells. (sciencedaily.com)
  • Importantly, the phenotypes, functions, and gene expression programs of T cells trained in variations of the system correlated well with those we found in T cells in mechanically distinct tissues from patients with cancer or fibrosis," said Mooney who also is the Robert P. Pinkas Family Professor of Bioengineering at SEAS, and leads the Wyss Institute's Immunomaterials Initiative. (sciencedaily.com)
  • Therefore, early in the formation of oral lichen planus lesions, CD8 + T cells may recognize an antigen associated with the major histocompatibility complex (MHC) class I on keratinocytes. (medscape.com)
  • After antigen recognition and activation, CD8 + cytotoxic T cells may trigger keratinocyte apoptosis. (medscape.com)
  • [ 8 ] T cells in oral lichen planus contain mRNA for TNF and secrete TNF in vitro. (medscape.com)
  • Focused on SNAP-CAR T Cells, a Platform Technology Being Developed to be Combined with Tagged, Tumor-Specific Antibodies to Potentially Target Many Different Tumor Types. (malvern-online.com)
  • Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible. (malvern-online.com)
  • Primary T cells expressing chimeric receptors specific for tumor or viral antigens have considerable therapeutic potential. (nih.gov)
  • We now report that EBV-specific (but not primary) T cells transduced with tumor-specific chimeric receptor genes can be expanded and maintained long-term in the presence of EBV-infected B cells. (nih.gov)
  • EBV-specific T cells expressing chimeric antitumor receptors may represent a new source of effector cells that would persist and function long-term after their transfer to cancer patients. (nih.gov)
  • Tumor-specific neoantigens, which are expressed on tumor cells, can induce an effective antitumor cytotoxic T-cell response and mediate tumor regression. (wjgnet.com)
  • T cells recognizing these peptides are found in cancer patients, but not in cancer-free individuals. (ntu.edu.sg)
  • T cells recognizing this unmodified peptide could be further stimulated in vitro to create effective cancer killing CTLs (cytotoxic T lymphocytes). (ntu.edu.sg)
  • Based in Prague, Czech Republic, Sotio is developing personalised dendritic cell vaccines (DCVACs) based on dendritic cells cultivated from a patient's blood monocytes and used to induce an immune response against tumour cells. (outsourcing-pharma.com)
  • The treatments involved a personalised preparation of the drug candidate using the dendritic cells, taken from the patient and manufactured by Sotio in vitro in large quantities. (outsourcing-pharma.com)
  • These cells process antigen material and present it on the cell surface to the T cells of the immune system, acting as messengers between the innate and the adaptive immune systems. (outsourcing-pharma.com)
  • Tumour cells (from cancer cell lines) killed by High Hydrostatic Pressure (HHP) are engulfed in these dendritic cells, before being reintroduced into the patient's body in the form of immunotherapeutic vaccine to trigger the required response from the patient's immune system against the harmful tumour cells. (outsourcing-pharma.com)
  • The company says the dendritic cells pulsed with the dead tumour cells have an increased ability to induce cytotoxic T cell responses, which increases the probability of inducing efficient immune response in the body. (outsourcing-pharma.com)
  • Targeting METTL3 by single-guide RNA, nanoparticle small interfering RNA (siRNA), or pharmacological inhibitor (STM2457) in combination with anti-programmed cell death protein 1 (PD-1) synergized to reinvigorate cytotoxic CD8+ T cells and mediate tumor regression. (bvsalud.org)
  • TRT agents bind tumor targets or accumulate within them, reducing toxicity to healthy cells relative to traditional external beam radiation therapy and allowing dose delivery to distant metastases. (pitt.edu)
  • One of the main functions of the cells of the immune system is to remove target cells that have been infected with viruses or have undergone transformation into a tumor cell. (jove.com)
  • In vitro assays for measuring the cytotoxic capacity of immune cells have been a staple in laboratories for many years. (jove.com)
  • These assays have been used to determine the ability of T cells, NK cells, or any other immune cell to kill target cells in an antigen-specific or -nonspecific manner. (jove.com)
  • These in vitro assays involve the mixing of different cell populations, as well as using a relatively low number of both effector and target cells. (jove.com)
  • As with any assay examining the function of immune cells in vitro , there are a number of important considerations to consider improving the performance of the experiment. (jove.com)
  • Dysregulation of various cells in the tumor microenvironment (TME) causes immunosuppressive functions and aggressive tumor growth. (biomedcentral.com)
  • This innovative approach enhances the patient's immune system to target and eliminate tumor cells. (biomedcentral.com)
  • Furthermore, inflammatory mediators released by irradiated dying cells can attract and regulate immune cells in the tumor microenvironment (TME), further killing cancer cells. (nature.com)
  • In addition, tumor-associated antigens (TAAs) produced by irradiated tumor cells can be captured by antigen-presenting cells (APCs) in the TME and presented to T cells. (nature.com)
  • B16-OVA tumors benefited from a synergistic effect, reaching 75% of tumor rejection, but higher levels of exhausted T-cells in LLC-OVA tumors co-expressing PD-1, LAG3 and TIM3 precluded similar levels of efficacy. (unav.edu)
  • Even though the idea of an immune system actively searching for and disposing of potential mutated tumor cells is over a century old, only recent developments in various fields such as mass spectrometry, immuno-checkpoint blockade strategies and in silico modelling have enabled the realization of the full potential of recruiting immune system to fight cancer and the possibilities of personalized therapies. (helsinki.fi)
  • These therapeutic methods, including but not limited to oncolytic virus therapies, T-cell therapies and cancer vaccines, are based on the body's ability to recognize mutated antigen peptides presented on the cell surface by MCH-receptors (also known as HLA-receptors in humans) and the disposal of the malignant cells by cytotoxic T-cells. (helsinki.fi)
  • This master thesis is a part of a project aiming to set up immunoaffinity-purification/MS based method in order to analyse the ligandome and determine T-cell recognized cancer associated antigens from tumor cells. (helsinki.fi)
  • Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model. (ox.ac.uk)
  • In a tumour setting, NK T cells activated by alpha-galactosylceramide (alpha-GalCer) execute anti-tumour activity by secreting cytokines. (ox.ac.uk)
  • Murine monoclonal antibodies are produced by injecting a mouse with an antigen, harvesting its spleen to obtain B cells that are producing antibody specific to that antigen, fusing those cells with immortal mouse myeloma cells, growing these hybridoma cells (eg, in cell culture), and harvesting the antibody. (msdmanuals.com)
  • In both cases, the process usually begins as above with production of mouse hybridoma cells that make antibody to the desired antigen. (msdmanuals.com)
  • Chimeric monoclonal antibodies activate antigen-presenting cells (APCs) and T cells more effectively than murine monoclonal antibodies but can still induce production of human anti-chimeric antibodies. (msdmanuals.com)
  • The real-time analysis in GBM-on-a-Chip showed that mesenchymal GBM niche attracted low number of allogeneic CD154+CD8+ T-cells but abundant CD163+ tumor-associated macrophages (TAMs), and expressed elevated PD-1/PD-L1 immune checkpoints and TGF-β1, IL-10, and CSF-1 cytokines compared to proneural GBM. (elifesciences.org)
  • By using direct reprogramming strategies, I could induce the expression of tumor antigens on the surface of cancer cells, making them visible to the immune system again. (lu.se)
  • We focused particularly on harnessing reprogramming, or direct cellular reprogramming, to induce antigen presentation in cancer cells. (lu.se)
  • when it comes to cancer they are critical as they present tumor antigens to the killer cells of the immune system and orchestrate the anti-tumor immune response. (lu.se)
  • Direct reprogramming strategies with cDC1-specific factors can induce antigen-presentation in cancer cells, making cancer cells visible to the immune system and easier to fight. (lu.se)
  • Shan J, Ma JM, Wang R, Liu QL, Fan Y. Proliferation and Apoptosis of Peripheral Blood Mononuclear Cells in Patients with Oral Lichen Planus. (medscape.com)
  • While inflammatory injury drives both fibrogenesis and carcinogenesis, the tolerogenic microenvironment of the liver conveys immunosuppressive effects that encourage tumor growth. (mdpi.com)
  • In conclusion, β-catenin drives a transcriptional switch in the lung tumor microenvironment, thereby promoting tumor progression and metastasis. (uni-frankfurt.de)
  • Accumulating research suggests that the tumor immune microenvironment (TIME) plays an essential role in regulation of tumor growth and metastasis. (biomedcentral.com)
  • Different tumor types can also design their specific microenvironment by encouraging tumor angiogenesis and stimulating peripheral immune tolerance. (biomedcentral.com)
  • This enhanced secretion of cholesterol and cholesteryl esters that impair CD8+ T cell function in the tumor microenvironment. (bvsalud.org)
  • Although RT is an important modality for cancer treatment, the consequential changes caused by RT in the tumor microenvironment (TME) have not yet been fully elucidated. (nature.com)
  • Integrative analyses of similar to 500 mice and similar to 1,000 patients revealed a common MAPK-MYC genetic pathway that accelerated time to progression from precursor states across genetically heterogeneous MM. MYC-dependent time to progression conditioned immune evasion mechanisms that remodeled the BM microenvironment differently. (unav.edu)
  • Chimeric antigen receptor (CAR) T-cell therapy is a rapidly growing treatment modality. (medscape.com)
  • The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
  • Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis. (jrheum.org)
  • The transmembrane and activation domains of the CAR-T receptor are responsible for activating and triggering T-cell proliferation when the receptor binds to its target antigen. (tufts.edu)
  • TCR-T therapy is developed to utilize a higher number of potential tumor antigens than other T cell-based immunotherapies, such as chimeric antigen receptor T cell (CAR-T) therapy. (medigene.com)
  • They recognize EBV-infected targets through their conventional T-cell receptor and tumor targets through their chimeric receptors. (nih.gov)
  • Despite the development of atypical antipsychotic drugs, parkinsonism is still a common problem among patients treated with these drugs as well as with dopamine receptor blocking antiemetics. (medlink.com)
  • The target-binding domain is engineered to be structurally different than endogenous T-cell receptors because it recognizes antigens that are independent of major histocompatibility complex (MHC) antigens. (tufts.edu)
  • Adoptive cell therapy using engineered T-cell receptors (TCRs) targeting cancer-testis antigens, such as Melanoma-associated antigen 3 (MAGE-A3), is a potential approach for the treatment of NSCLC. (thno.org)
  • Proteins of the major histocompatibility complex (MHC) class I, or human leukocyte antigen (HLA) in humans interact with endogenous peptides and present them to T cell receptors (TCR), which in turn tune the immune system to recognize and discriminate between self and foreign (non-self) peptides. (ntu.edu.sg)
  • Inflammatory cytokines are usually added to aid in antigen uptake and recognition by PBMCs. (wikipedia.org)
  • While tumor expansion, contact-dependent or independent crosstalk between tumor and TIME affects the production of various cytokines that help in the polarization of antitumor immune response in the immunosuppressive TIME. (biomedcentral.com)
  • The early CYT-338 data, showing superiority over daratumumab in several in vitro assays, is similarly impressive and warrants further preclinical development in my opinion. (biospace.com)
  • IFN-γ release assays (IGRAs) are in vitro blood tests that measure T-cell release of IFN-γ after stimulation with antigens unique to Mycobacterium tuberculosis . (atsjournals.org)
  • 2. Interferon γ cytokine secretion was determined by ELISPOT to assess PBMC response against known antigens in a preliminary experiment to approximate usable range for the following antigen specific PBMC assays. (helsinki.fi)
  • Characterized by cell-surface molecules including CD103, CD69, and CD49a, T RM -like tumor-infiltrating lymphocytes (TILs) can be found in a wide range of human cancers, where they portend improved prognosis. (frontiersin.org)
  • Reports of spontaneous regression and tumour infiltration with T-lymphocytes makes melanoma candidate for immunotherapies. (mdpi.com)
  • 3 Autologous lymphocytes genetically modified with the TCR for MART-1/Melan-A have been adoptively transferred to patients with advanced melanoma. (haematologica.org)
  • 4 According to the number of tumor-infiltrating lymphocytes, tumors can be divided into three phenotypes: immune-inflamed, immune-excluded, and immune-desert types. (nature.com)
  • CD44 percentage values in peripheral T-lymphocytes were significantly higher in patients than controls, as detected by flow cytometry. (who.int)
  • Le pourcentage de CD44 dans les lymphocytes T périphériques était significativement plus élevé chez les patients que chez les témoins, comme détecté par la cytométrie en flux. (who.int)
  • CD8 + T-cell proliferation and cytokine secretion were assessed in an antigen-specific assay using claudin-6 as a model antigen. (bmj.com)
  • Oral lichen planus lesions contain increased levels of the cytokine tumor necrosis factor (TNF)-alpha. (medscape.com)
  • Furthermore, in both CD8+ T cell populations the majority of the tumor-specific CTL exhibited a Th1 cytokine bias (IFN-γ high /IL-4 low ). (utmb.edu)
  • Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. (stanfordchildrens.org)
  • This single-arm exploratory pilot study of adult patients with AIH aimed to define the impact of an 8-week MBSR program on quality of life, disease activity, and cytokine mediators.Methods: The perceived stress survey-10 (PSS) and the brief self-control scale (BSCS) measured subjective distress and self-control. (stanfordchildrens.org)
  • Serum alanine aminotransferase (ALT) and cytokine levels were measured, and immunosuppressant doses recorded.Results: Seventeen patients completed the MBSR program. (stanfordchildrens.org)
  • Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. (biospace.com)
  • The COEP CD38 Diagnostic is designed to be used as a companion with CD38 GEAR-NK or as a standalone diagnostic screening test to determine which immunotherapies may be responsive to CD38+ tumors. (malvern-online.com)
  • Among tumor immunotherapies, neoantigen vaccines are in early human clinical trials and have demonstrated substantial efficiency. (wjgnet.com)
  • Understanding the stroma's role in blocking anti-tumor immune function is an essential step towards to overcoming this hurdle. (medicalxpress.com)
  • Although immune checkpoint blockade (ICB) reinvigorates anti-tumor immune responses by disrupting co-inhibitory T-cell signaling, relapse frequently occurs after ICB treatment and acquired resistance often emergence after initial response [ 4 ]. (thno.org)
  • However, vaccines targeting TAAs have demonstrated disappointing clinical results, reflecting poor antigen selection and/or immunosuppressive mechanisms. (cardiff.ac.uk)
  • The processes of tumor initiation, expansion, and metastasis are governed by the TIME, where immunosuppressive and antitumor immune crosstalk play an important role. (biomedcentral.com)
  • My Ph.D. studies have focused on restoring anti-tumor immunity with dendritic cell reprogramming strategies. (lu.se)
  • In ICI-resistant mouse models, an optimal low-dose TRT range was determined from subject-specific dosimetry for combined TRT + ICI that led to complete tumor regression in most mice. (pitt.edu)
  • Effect of anti-tumor necrosis factor on work disability. (jrheum.org)
  • Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon? (jrheum.org)
  • Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. (jrheum.org)
  • The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. (jrheum.org)
  • Here we review the data for the use of QuantiFERON-TB Gold In-Tube and T-SPOT.TB, the two currently available IGRAs, in immunocompromised adults, including persons infected with HIV, patients with immune-mediated inflammatory disorders, candidates for treatment with tumor necrosis factor-α inhibitors, patients receiving hemodialysis, solid-organ transplant recipients, and patients with cancer. (atsjournals.org)
  • The expression or unmasking of the lichen planus antigen may be induced by drugs (lichenoid drug reaction), contact allergens in dental restorative materials or toothpastes (contact hypersensitivity reaction), mechanical trauma (Koebner phenomenon), viral infection, or other unidentified agents. (medscape.com)
  • The lichen planus antigen is unknown, although it may be a self-peptide (or altered self-peptide), in which case lichen planus would be a true autoimmune disease. (medscape.com)
  • Although epigenetically silenced, endogenous retroviral (ERV) genes become activated in tumors and function to ignite immune responses. (frontiersin.org)
  • Injection of in vitro generated melanoma-derived tumor-APCs into subcutaneous melanoma tumors delayed tumor growth and increased survival in mice. (lu.se)
  • It is expressed in many tumors and is strongly immunogenic in patients with cancers originating from a variety of sites. (cardiff.ac.uk)
  • The COEP product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which COEP is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. (malvern-online.com)
  • T RM responses against tumor/self-antigens can concurrently result in the development of pathogenic T RM responses to self, with a growing number of autoimmune diseases and inflammatory pathologies being attributed to T RM responses. (frontiersin.org)
  • they are used to treat solid and hematopoietic tumors, inflammatory disorders, and infections. (msdmanuals.com)
  • Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a glycoprotein that has limited expression in normal adult tissues, but is overexpressed in carcinomas of the gastrointestinal tract, the genitourinary and respiratory systems, and breast cancer. (nih.gov)
  • The introduction of well-defined monoclonal antibodies against clearly defined epitopes of the CEA family will make the differential diagnosis of tumors easier. (karger.com)
  • Methods The effects of combining HexaBody-CD27 with anti-PD-(L)1 antibodies (pembrolizumab, nivolumab, and atezolizumab) on human CD8 + T-cell proliferation and effector functions were investigated in vitro . (bmj.com)
  • Instead, CAR-T recognizes antigens that are either proteins, carbohydrates, or gangliosides on the tumor cell surface. (tufts.edu)
  • Subsequently, PBMCs are challenged with tumor antigens such as tumor stem cell antigen. (wikipedia.org)
  • Autophagy may represent a mechanism of resistance to oxidative stress induced by chemotherapeutic drugs and may potentiate cancer cell survival to hypoxia and nutrient starvation due to the frequently defective tumor vascularization. (nature.com)
  • The first report of CAR T-cell therapy was in 2010, in a patient with advanced follicular lymphoma. (medscape.com)
  • T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies. (hindawi.com)
  • Sixteen histological tumor subtypes exist and the most common are papillary, chromophobe and clear cell renal cell carcinoma (ccRCC) representing 85% of all RCC. (frontiersin.org)
  • CMN-001 is indicated for the treatment of intermediate/poor-risk patients with advanced renal cell carcinoma (RCC) in combination with nivolumab plus ipilimumab as first-line therapy and in combination with lenvatinib plus everolimus as 2nd line therapy post-first-line failure. (moffitt.org)
  • T cell memory is antigen-specific, and can provide durable host-wide protection. (frontiersin.org)
  • Combining tumor-specific adoptive T cell therapy to the aCTLA-4/aPD1/rIL2 or aCTLA-4/aPD1/aCD137 reg-imens enhances efficacy in a synergistic manner. (unav.edu)
  • However, systematic analysis of T cell immune responses to MAGE-A3 antigen and corresponding antigen-specific TCR is still lacking. (thno.org)
  • This importance is focussed on the target binding site - epitope, where epitope selection as a part of design thinking beyond traditional antigen selection using whole cell or whole protein immunisation can positively impact success. (preprints.org)
  • These initial results encouraged us to undertake preclinical investigations with immunotoxins directed against the B-cell restricted CD19 antigen for B-lymphoid tumors and against the CD38 molecule for multiple myeloma. (atsbio.com)
  • A poignant reminder here was the disastrous peripheral nerve damage experienced by women with breast cancer treated with a ricin A chain-based immunotoxin which unexpectedly also targeted nervous tissue.4 The most sensitive in vitro method for determining the selective cytotoxic potency of saporin-based immunotoxins is by measuring their ability to selectively inhibit protein synthesis in antigen-expressing cell lines in a dose-dependent manner. (atsbio.com)
  • tumor cell purification was essential to reveal these genes. (cardiff.ac.uk)
  • Candidate TAA protein expression was confirmed by immunohistochemistry, and pre-existing T cell immunogenicity towards these antigens tested. (cardiff.ac.uk)
  • Through tumor cell purification and sequencing, novel candidate TAAs have been identified for future immunotherapeutic targeting. (cardiff.ac.uk)
  • Therefore, understanding the TME and its immune cell components are equally important as cancer cell characteristics for tumor eradication. (biomedcentral.com)
  • This new concept could help advance adaptive T cell therapies by producing desired patient-specific T cell populations in the dish that could provide stronger effects when infused back into the same patient. (sciencedaily.com)
  • But improving the ability to create patient-specific T cell populations with specific traits and functions could broaden clinicians' repertoire of T cell therapies. (sciencedaily.com)
  • The role of autoimmunity in the pathogenesis is supported by many autoimmune features of oral lichen planus, including its chronicity, onset in adults, predilection for females, association with other autoimmune diseases, occasional tissue-type associations, depressed immune-suppressor activity in patients with oral lichen planus, and the presence of autocytotoxic T-cell clones in lichen planus lesions. (medscape.com)
  • COEP ) together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. (malvern-online.com)
  • In this study we evaluated the potential of tumor antigen-pulsed fully mature dendritic cell (DC) stimulation in restoring tumor-specific cytotoxicity in anergic TIL populations from advanced breast cancer patients. (utmb.edu)
  • In addition we have compared tumor-specific T cell responses induced by tumor antigen-loaded DC stimulation of TIL to responses induced from PBL. (utmb.edu)
  • Sotio has selected local CRO Accord Research to carry out Phase I/II trials on its dendritic cell vaccines to treat patients with lung cancer in the Czech Republic. (outsourcing-pharma.com)
  • The cytotoxic activity of SAR408701 was assessed in CEACAM5-expressing tumor cell lines and using patient-derived xenograft mouse models of CEACAM5-positive tumors. (nih.gov)
  • IRE uses HVEPs to cause cell death by inducing membrane disruption, and it is primarily used as a radical ablative therapy in the treatment of soft-tissue tumors in the liver, kidney, prostate, and pancreas. (rsna.org)
  • A phase II study showed that patients with resected local-regionally advanced head and neck squamous cell carcinoma (HNSCC) had improved survival when pembrolizumab was added to adjuvant RT (NCT02641093). (nature.com)
  • In clinical series, high CD8(+) T/T-reg cell ratios underlie early progression in untreated smoldering MM, and correlated with early relapse in newly diagnosed patients with MM under Len/Dex therapy. (unav.edu)
  • This improved efficacy was associated with higher tumor T-cell infiltration and overexpression of PD-1/PD-L1. (unav.edu)
  • Characterizing tumor cell lines. (helsinki.fi)
  • In this study, we have shown that T(regs) regulate NK T cell function negatively in vitro, suggesting a direct interaction between these cell types. (ox.ac.uk)
  • In vitro studies based on MCF-7 cell proliferation and induction of vitellogenin in primary culture of rainbow trout hepatocytes. (cdc.gov)
  • The authors used artificial neural croarrays is to study changes in gene ex- .nature organ the tumor arose from, how big it networks (ANNs) to identify gene-ex- pression that accompany changes in is, and what it looks like after it has pression signatures associated with spe- cell physiology, such as during develop- been imbedded in wax and colored cific subtypes of tumors. (lu.se)
  • 0 blue-cell tumors (SRBCTs), which type, 41 (including 7 expressed often masquerade as each other. (lu.se)
  • PBMCs from cancer patients can be extracted and cultured in vitro. (wikipedia.org)
  • Research has intensified to understand ERV protein function and their role as tumor antigens and targets for cancer (immune) therapy. (frontiersin.org)
  • Taking Care of Your Health features cancer-related information, health tips, patient stories and more. (moffitt.org)
  • Emerging data suggest that the combination of DC-based vaccination with other cancer therapies may fully unleash the potential of DC-based cancer vaccines and improve patient survival. (moffitt.org)
  • The Breast Oncology Department , for example, has developed innovative clinical trials for vaccines that offer new ways to treat various types and stages of breast cancer and improve patient outcomes. (moffitt.org)
  • If you'd like to refer a patient to Moffitt Cancer Center, complete our online form or contact a physician liaison for assistance. (moffitt.org)
  • For the large number of hepatocellular cancer patients who currently have such limited, poor clinical options, a novel tumor antigen-directed NK engager is needed. (biospace.com)
  • The Netherlands Cancer Institute is among the world's best comprehensive cancer centers, combining innovative fundamental, translational, and clinical research with dedicated patient care. (nki.nl)
  • Although the technology is not perfect, there is optimism in the field that CAR-T can radically improve cancer patient care. (tufts.edu)
  • The importance of stroma also seems to vary between cancer types, and is particularly striking in pancreatic ductal adenocarcinoma, a type of pancreatic cancer in which stroma can represent more than 90% of the tumor volume. (medicalxpress.com)
  • Upon mRNA intratumoral injections in the transplantable mouse cancer models CT26, MC38, and B16OVA, potent therapeutic effects were observed following repeated injections into the tumors. (unav.edu)
  • Results: The most promising candidate for further development is DNAJB7 [DnaJ heat shock protein family (Hsp40) member B7], identified here as a novel cancer-testis antigen. (cardiff.ac.uk)
  • Moreover, we found that high expressions of β-catenin and FOSL2 correlated with poor prognosis in patients with lung cancer. (uni-frankfurt.de)
  • The cellular and molecular nature of the TIME influences cancer progression and metastasis by altering the ratio of immune- suppressive versus cytotoxic responses in the vicinity of the tumor. (biomedcentral.com)
  • RNA-dependent targeting of the TIME, as monotherapy or combined with other evolving therapeutics, might be beneficial for cancer patients' treatment in the near future. (biomedcentral.com)
  • Taken together, these data show that tumor lysate-pulsed mature DC can consistently restore tumor-specific lytic activity in non-cytotoxic breast cancer TIL. (utmb.edu)
  • Its lead product, DCVAC/PCa, is in Phase III trials to treat patients with prostate cancer. (outsourcing-pharma.com)
  • Yesterday the firm announced enrolment has begun for a Phase I/II clinical trial to determine safety and efficacy of the vaccine DCVAC/LuCa in combination with standard chemotherapy in patients with lung cancer, with the trial being carried out by local contract research organisation (CRO) Accord Research. (outsourcing-pharma.com)
  • Currently the vaccines are being tested in combination standard chemotherapy on patients with ovarian cancer, as well as prostate and lung cancer. (outsourcing-pharma.com)
  • Targeted radiopharmaceutical therapy (TRT) involving systemic administration of a tumor-selective agent labeled with a radionuclide has demonstrated considerable promise for cancer treatment, gaining traction recently with FDA approval of two agents since 2018. (pitt.edu)
  • The dysfunction of LSD1 contributes to poor prognosis, poor patient survival, drug resistance, immunosuppression, etc., making it a potential epigenetic target for cancer therapy. (biomedcentral.com)
  • Patients who are radioresistant respond poorly to RT and may experience cancer progression. (nature.com)
  • Over half of cancer patients undergo radiation therapy (RT). (nature.com)
  • To observe and follow-up cancer patients who insisted on using camel urine, and to offer some clinically relevant recommendations. (who.int)
  • We observed 20 cancer patients (15 male, 5 female) from September 2020 to January 2022 who insisted on using camel urine for treatment. (who.int)
  • Camel urine had no clinical benefits for any of the cancer patients, it may even have caused zoonotic infection. (who.int)
  • One of the commonly cancer patients who insisted upon using camel urine, to used forms of complementary and alternative medicine establish exactly how they administered the urine and is camel urine alone or in combination with camel whether there were any clinical benefits or harm. (who.int)
  • Many of these factors stem from the location of the epitope that can affect accessibility of the antibody to the epitope at a cellular or molecular level, direct inhibition of target antigen activity, conservation of function despite escape mutations, and even non-competitive inhibition sites. (preprints.org)
  • SEE NAMCS PATIENT DATASET NAMES FOR DSN ABSTRACT General Information This material provides documentation for users of the Micro-Data tapes of the National Ambulatory Medical Care Survey (NAMCS) conducted by the National Center for Health Statistics. (cdc.gov)
  • Whilst there have been anti-tumor responses with ricin-based immunotoxins, particularly in hematological malignancies,2 their toxicity profile has limited their clinical usefulness and interest in their utility has consequently dropped away. (atsbio.com)
  • Two patients showed dramatic responses to treatment and no serious side effects were observed. (atsbio.com)
  • By contrast, T(regs) intrinsically suppress antigen-specific immune responses and are often found to be elevated in tumour patients. (ox.ac.uk)
  • However, responses vary significantly among eligible patients. (lu.se)
  • Approximately 98% of children with ALL attain complete remission (CR) with standard treatment, and 85% of patients aged 1 to 18 years with newly diagnosed ALL treated with current regimens have long-term event-free survival. (medscape.com)
  • High ERV-K env total protein expression of all tumor subtypes significantly correlated with low tumor grading and a longer disease specific survival using multivariable analyses. (frontiersin.org)
  • This study supports ERV-K env as a single prognostic indicator for better survival of RCC, which we propose represents a new tumor antigen. (frontiersin.org)
  • We show that treatment of the mice with a combination of anti-CTLA-4 + anti-PD1 mAbs results in partial clearance of the tumor with an improvement in survival. (unav.edu)
  • Despite the recent advances in the treatment of NSCLC, including surgery, chemotherapy, radiotherapy and targeted therapy, there has been little improvement in overall patient survival [ 3 ]. (thno.org)
  • Antitumor immunity elicited by tumor-APCs was synergistic with immune checkpoint inhibitors. (lu.se)
  • Immune checkpoint-inhibitor combinations are the best therapeutic option for advanced hepatocellular car-cinoma (HCC) patients, but improvements in efficacy are needed to improve response rates. (unav.edu)
  • Vaccination using optimized strategies may increase response rates to immune checkpoint inhibitors (ICI) in some tumors. (unav.edu)
  • Such preclinical investigations are mandatory to justify taking an experimental drug into patients and to ensure, as far as possible, safety of the drug. (atsbio.com)
  • On the basis of these preclinical data, the ADC SAR408701 is a promising candidate for development as a potential treatment for patients with CEACAM5-positive tumors. (nih.gov)
  • [ 9 ] Serum and salivary TNF levels are elevated in oral lichen planus patients. (medscape.com)
  • Of possible significance, elevated concentrations of interleukin-6 (IL-6) and neopterin in saliva and serum of patients with the erosive-atrophic form of oral lichen planus suggest they may be involved in the etiology of this disease variation. (medscape.com)
  • [ 20 ] Additionally, microRNA 4484 (miR-4484) has been found to be significantly up-regulated in the salivary exosomes of patients with oral lichen planus. (medscape.com)
  • 22] Oral lichen planus is a common noninfectious oral mucosal disorder among adult patients who attend oral pathology and oral medicine clinics. (medscape.com)
  • Complete history taking and physical examination by a dermatologist may be required in patients with extra-oral symptoms or signs associated with oral lichen planus. (medscape.com)
  • In many patients, the onset of oral lichen planus is insidious, and patients are unaware of their oral condition. (medscape.com)
  • Approximately two thirds of patients with oral lichen planus report oral discomfort, especially in association with atrophic and erosive lesions. (medscape.com)
  • There are still significant barriers to therapeutic success because of tumor-specific antigens (TA) and toxicities associated with treatment [ 19 ]. (biomedcentral.com)
  • ECT uses HVEPs to transiently increase membrane permeability, enhancing cellular cytotoxic drug uptake in tumors. (rsna.org)
  • The FLEX-NK TM multifunctional engager antibody CYT-338 directed against NKp46 and CD38 demonstrated in vitro activity against multiple myeloma tumor targets. (biospace.com)
  • These tumors and accessories represent the hallmark characteristics that support tumor progression and lead to metastasis. (biomedcentral.com)
  • The ratio of pro- to antitumor immune populations in the TIME plays a critical role in the regulation of tumor progression and metastasis. (biomedcentral.com)
  • Tumor-associated macrophages (TAMs) influence lung tumor development by inducing immunosuppression. (uni-frankfurt.de)
  • Transcriptome analysis of TAMs isolated from human lung tumor tissues revealed an up-regulation of the Wnt/β-catenin pathway. (uni-frankfurt.de)
  • An in-depth analysis of the underlying signaling events revealed that β-catenin-mediated transcriptional activation of FOS-like antigen 2 (FOSL2) and repression of the AT-rich interaction domain 5A (ARID5A) drive gene regulatory switch from M1-like TAMs to M2-like TAMs. (uni-frankfurt.de)
  • In this investigation a human RCC tissue microarray (TMA) (n=374) predominantly consisting of the most common histological tumor subtypes was hybridized with an ERV-K env antibody and correlated with patient clinical data. (frontiersin.org)
  • Through the incorporation of novel computational methods for predicting antigen changes to model-informed drug discovery and development, superior vaccines and antibody-based therapeutics or diagnostics can now be more easily designed to mitigate failures. (preprints.org)
  • The earliest study was conducted by Falini and his associates3 in Italy and Germany utilizing a CD30 antibody coupled to saporin for the treatment of four patients with advanced Hodgkin's disease. (atsbio.com)
  • As such, CEACAM5 is an attractive target for antibody-based therapies designed to selectively deliver cytotoxic drugs to certain epithelial tumors. (nih.gov)
  • The likelihood of progression to active TB can be substantially reduced by identification and treatment of patients with LTBI ( 5 , 6 ). (atsjournals.org)
  • Combining this therapy with ICI may provide only modest benefit, and patients experiencing tumor progression have no reliable alternatives. (pitt.edu)
  • We showed that targeting those fibroblasts can disrupt that barrier and has a very great tumor inhibition effect. (medicalxpress.com)
  • However, GBM, a very aggressive brain tumor with poor prognosis even after surgery and radio-chemotherapy, invariably recurs and leads to patient death. (nature.com)
  • First, we compared the prevalence of patient diagnoses in pediatric and adult populations to identify disease phenotypes differentially affecting children and adults. (bvsalud.org)
  • On the basis of the available data, IGRAs have advantages over the tuberculin skin test in specific patient populations and in certain situations. (atsjournals.org)
  • Tissue sample from 30-year-old primigravida patient patients with presumed infl uenza. (cdc.gov)
  • Unlike alternative ablative therapies, electroporation does not affect the structural integrity of surrounding tissue, thereby enabling tumors in the vicinity of vital structures to be treated. (rsna.org)
  • The tumor was predicted to receive significantly more 67Cu dose than any other tissue, including the often dose-limiting kidneys. (pitt.edu)
  • For this reason, the first clinical trials of CAR-T created damaging side effects and in some cases the therapy was associated with patient deaths. (tufts.edu)
  • The mechanical features of tissues, for example, bone, muscle, different internal organs, and blood, can vary widely, and pathological tissues such as tumor masses or fibrotic tissues are mechanically significantly different from healthy tissues. (sciencedaily.com)
  • The tuberculin skin test, the traditional assay for diagnosing LTBI, has reduced accuracy in immunocompromised patients. (atsjournals.org)